China Lipid Disorder Therapeutics Market Analysis

China Lipid Disorder Therapeutics Market Executive Summary

China Lipid Disorder Therapeutics Market is at around $262.6 Mn in 2023 and is projected to reach to $532.6 Mn in 2030, exhibiting a CAGR of 10.63% during the forecast period.

An excessive amount of fats or lipids in the bloodstream is referred to as a lipid disease. A higher risk of heart disease and stroke can result from having elevated levels of triglycerides or cholesterol. A patient may experience no symptoms at first, but over time they may appear as fatty deposits around the eyes (xanthelasmas), yellowish deposits on the skin (xanthomas), or chest pain. A good diet, regular exercise, and giving up smoking are examples of lifestyle modifications that are frequently part of treatment. Other medications that can be recommended to assist in decreasing cholesterol levels include fibrates or statins. For accurate diagnosis and treatment, speaking with a healthcare provider is essential.

The prevalence of dyslipidemia (abnormal cholesterol levels) in China is around 30%, according to a 2017 study in eastern China. This means nearly a third of adults have high cholesterol or triglycerides. Age, lifestyle factors like smoking and diet, and pre-existing conditions like diabetes all contribute to higher risk. The market therefore is driven by significant factors like Increasing Healthcare Expenditure, Rising Prevalence of Dyslipidemia, and Expanding Treatment Guidelines. However, Regulatory Challenges, Generic Competition, Drug Safety Concerns, and Lifestyle Changes as Alternative restrict the growth and potential of the market.

Sun Pharma launches a first-in-class oral drug, Bempedoic Acid for reducing LDL cholesterol under the brand name Brillo.

Market Dynamics

Market Growth Drivers

Increasing Healthcare Expenditure: The Chinese government is placing a growing emphasis on healthcare, leading to rising healthcare expenditure. This translates to greater investment in chronic disease management, including dyslipidemia, which benefits the therapeutics market.

Rising Prevalence of Dyslipidemia: Dyslipidemia, characterized by abnormal cholesterol and triglyceride levels, affects a substantial portion of the Chinese population. Studies suggest a prevalence rate of around 30%, with a significant increase with age. This large and growing patient pool creates a strong demand for therapeutic interventions.

Expanding Treatment Guidelines: Medical advancements and updated treatment guidelines are recommending statin therapy and other lipid-lowering medications for a wider range of patients. This broader application of these therapies expands the market size.

Market Restraints

Regulatory Challenges: The stringent regulatory environment for pharmaceutical products in China poses another restraint. The approval process for new drugs can be lengthy and complex, delaying the introduction of innovative therapies into the market. Additionally, ongoing updates to national guidelines, require continuous compliance, which can be resource-intensive for pharmaceutical companies​.

Generic Competition: The market for established statin drugs is highly competitive, with numerous generic options available. This competition drives down prices and can limit profitability for pharmaceutical companies developing innovative therapies.

Drug Safety Concerns: Recent concerns about the safety profile of certain lipid-lowering medications, particularly regarding potential side effects, may lead to some patients being hesitant to take these medications or physicians being more cautious in prescribing them.

Lifestyle Changes as Alternative: Lifestyle modifications, including dietary changes, exercise, and weight management, are crucial in managing cholesterol levels. Some individuals may prefer or be recommended to focus on lifestyle changes first, leading to a lower demand for pharmacological interventions.

Regulatory Landscape and Reimbursement Scenario

All imported medications and medical devices must register or undergo a notification filing process with the National Medical Products Administration (NMPA, formerly known as CFDA) before being marketed or distributed in the Chinese market. Good Clinical Practice (GCP), Good Manufacturing Practices (GMP) abroad, the "Generic Drugs Quality Consistency Evaluation" (GQCE), and the validation of pharmaceutical manufacturing procedures have been in place in order to monitor the production of generics.

China's health insurance program will be supervised by the Health Security Administration (HSA). China's healthcare system has advanced significantly in recent years, and in order to achieve even greater progress, many parts of the current medical care system are still being examined. The healthcare insurance system established by the Chinese government provides benefits to approximately 1.36 Bn people and covers about 96% of the population. Additionally, there is a large array of private healthcare solutions accessible, and it is possible to add private insurance to public health insurance.

Competitive Landscape

Key Players

Here are some of the major key players in the China Lipid Disorder Therapeutics Market:

• Sanofi
• Sun Pharmaceutical Industries Ltd.
• Pfizer, Inc.
• GlaxoSmithKline plc
• Novartis AG
• Merck & Co., Inc.
• Amgen Inc.
• Takeda Pharmaceutical Company Limited
• AbbVie, Inc.
• Viatris
• AstraZeneca PLC
• Dr. Reddy’s Laboratories Ltd.